Repligen (NASDAQ:RGEN) Shares Gap Up to $157.48

Repligen Co. (NASDAQ:RGEN)’s stock price gapped up prior to trading on Tuesday . The stock had previously closed at $157.48, but opened at $166.49. Repligen shares last traded at $171.99, with a volume of 139,951 shares changing hands.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. Stifel Nicolaus upped their target price on shares of Repligen from $165.00 to $207.00 and gave the company a “buy” rating in a research note on Thursday, February 22nd. KeyCorp upped their price target on shares of Repligen from $210.00 to $220.00 and gave the company an “overweight” rating in a report on Thursday, February 15th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $196.70.

Repligen Price Performance

The company’s fifty day moving average is $185.86 and its 200 day moving average is $173.52. The firm has a market cap of $9.37 billion, a price-to-earnings ratio of 233.14, a PEG ratio of 5.61 and a beta of 1.02. The company has a quick ratio of 5.75, a current ratio of 7.02 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last announced its earnings results on Wednesday, February 21st. The biotechnology company reported $0.33 EPS for the quarter, hitting the consensus estimate of $0.33. Repligen had a net margin of 6.51% and a return on equity of 5.00%. The business had revenue of $155.74 million during the quarter, compared to analysts’ expectations of $155.38 million. During the same quarter in the prior year, the company posted $0.68 earnings per share. The firm’s revenue was down 16.6% on a year-over-year basis. On average, equities research analysts predict that Repligen Co. will post 1.46 EPS for the current year.

Insider Buying and Selling

In related news, Director Karen A. Dawes sold 1,000 shares of the stock in a transaction on Tuesday, February 27th. The shares were sold at an average price of $193.35, for a total transaction of $193,350.00. Following the completion of the transaction, the director now owns 87,367 shares in the company, valued at $16,892,409.45. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Repligen news, VP Ralf Kuriyel sold 3,517 shares of the stock in a transaction on Monday, March 11th. The shares were sold at an average price of $193.73, for a total value of $681,348.41. Following the completion of the sale, the vice president now owns 24,260 shares in the company, valued at $4,699,889.80. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Karen A. Dawes sold 1,000 shares of the stock in a transaction on Tuesday, February 27th. The shares were sold at an average price of $193.35, for a total transaction of $193,350.00. Following the completion of the sale, the director now owns 87,367 shares of the company’s stock, valued at approximately $16,892,409.45. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 25,597 shares of company stock worth $5,039,532. 1.20% of the stock is owned by insiders.

Institutional Trading of Repligen

A number of large investors have recently added to or reduced their stakes in RGEN. DekaBank Deutsche Girozentrale raised its position in shares of Repligen by 1.5% in the third quarter. DekaBank Deutsche Girozentrale now owns 10,457 shares of the biotechnology company’s stock valued at $1,663,000 after purchasing an additional 159 shares during the period. International Assets Investment Management LLC raised its position in shares of Repligen by 18,449.1% in the fourth quarter. International Assets Investment Management LLC now owns 58,615 shares of the biotechnology company’s stock valued at $10,539,000 after purchasing an additional 58,299 shares during the period. American Century Companies Inc. raised its position in shares of Repligen by 97.5% in the third quarter. American Century Companies Inc. now owns 217,900 shares of the biotechnology company’s stock valued at $34,648,000 after purchasing an additional 107,570 shares during the period. Louisiana State Employees Retirement System bought a new position in shares of Repligen in the fourth quarter valued at about $2,625,000. Finally, Atria Investments Inc bought a new position in shares of Repligen in the third quarter valued at about $1,046,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.